<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene Q493K literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.Q493K</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Mutation from chronically infected patient predicted to introduce clash with potent mAbs C1A-VH3-53,  and verified by pseudovirus assay against the weaker mAbs in this family.<br/>The mutation conferred decreased sensitivity to mAb B38 but had no effect on neutralization by mAb CC12. (<a href="https://doi.org/10.1016/j.cell.2021.03.027" class="lit_link">Clark et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="immunosuppression_variant_emergence">Immunosuppression variant emergence</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Intermittent appearance at Day 128 onward of long infection in patient on escalated immunosupressed starting Day 111 (<a href="https://doi.org/10.1056/NEJMc2031364" class="lit_link">Choi et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Escapes mAb REGN10987, part of Regeneron's antibody cocktail. <br/> (<a href="https://doi.org/10.1101/2020.11.30.405472" class="lit_link">Starr et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Strong positive selection (up to 45% of supernatant sequences) under two rounds of C121 monoclonal antibody passage.<br/>Strong positive selection (up to 39% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R (<a href="https://doi.org/10.1101/2020.07.21.214759" class="lit_link">Weisblum et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Leads to a 14-fold reduction in neutralization efficiency for REGN10933.<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.027" class="lit_link">Clark et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
